Horizon’s Saint John Regional Hospital to become Canada’s first to adopt Subtle Medical’s AI solutions

Subtle Medical, a healthcare technology company using artificial intelligence to improve medical imaging, announced today the first commercial adoption of SubtlePET™ in Canada to help improve the quality and efficiency of PET imaging.

The launch was made possible by support from the Saint John Regional Hospital Foundation, a charitable organization focused on providing exceptional health care in New Brunswick.

Through the Foundation’s Medical Competition, funding was made available for the adoption of Subtle Medical’s deep learning technology, SubtlePET™, which earned recognition after demonstrating the ability to dramatically improve patient comfort and safety during medical imaging by giving imaging institutions the ability to restore image quality to standard of care when conducting shorter and lower dose PET exams.

“Our doctors and healthcare workers are constantly looking for ways to bring medical innovation and new clinical programs to life. They are backed by an ambitious and progressive foundation that’s continually striving to support them by investing in healthcare innovation for the benefit of all New Brunswickers. We look forward to seeing these new innovations in practice,” says Jamie Gallagher, President & CEO for the Foundation.

Shorter scan times are particularly beneficial to children and patients who experience pain and anxiety during these procedures. Reducing scan times could also allow institutions to schedule more patients a day on their existing scanners, resulting in shorter wait times for patients in critical need of medical imaging.

“The launch of Subtle’s AI solutions is one step further in supporting Horizon’s goal of prioritizing patient-centered care,” said Zach Kilburn, Regional Director of Diagnostic Imaging for Horizon Health Network. “The SubtlePET technology not only improves patient experience during procedures, but also allows us to see more patients, creating a better, more efficient imaging program at our center.”

“We are grateful for the support from The Saint John Regional Hospital Foundation and proud that Horizon Health Network is the first to use Subtle Medical’s AI solutions in Canada,” said Josh Gurewitz, Chief Commercial Officer at Subtle Medical. “The Canadian healthcare system is among the best in the world, so it’s only natural that hospitals and medical centers recognize the critical role AI plays in improving healthcare inefficiencies and providing the highest level of care to their patients.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”